ZA200510256B - N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases - Google Patents
N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases Download PDFInfo
- Publication number
- ZA200510256B ZA200510256B ZA200510256A ZA200510256A ZA200510256B ZA 200510256 B ZA200510256 B ZA 200510256B ZA 200510256 A ZA200510256 A ZA 200510256A ZA 200510256 A ZA200510256 A ZA 200510256A ZA 200510256 B ZA200510256 B ZA 200510256B
- Authority
- ZA
- South Africa
- Prior art keywords
- piperazine
- phenyl
- methyl
- fluoro
- chloro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 237
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 117
- 238000011282 treatment Methods 0.000 title claims description 77
- 238000011321 prophylaxis Methods 0.000 title claims description 33
- 201000010099 disease Diseases 0.000 title description 46
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 title description 7
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 353
- -1 CFs Inorganic materials 0.000 claims description 171
- 239000000203 mixture Substances 0.000 claims description 84
- 208000035475 disorder Diseases 0.000 claims description 71
- 210000003169 central nervous system Anatomy 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 48
- 239000000126 substance Substances 0.000 claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 241000124008 Mammalia Species 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 36
- 239000000556 agonist Substances 0.000 claims description 32
- 208000024827 Alzheimer disease Diseases 0.000 claims description 31
- 230000006378 damage Effects 0.000 claims description 26
- 230000002265 prevention Effects 0.000 claims description 26
- 208000008589 Obesity Diseases 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 25
- 125000001188 haloalkyl group Chemical group 0.000 claims description 25
- 235000020824 obesity Nutrition 0.000 claims description 25
- 229910052801 chlorine Inorganic materials 0.000 claims description 24
- 229910052731 fluorine Inorganic materials 0.000 claims description 24
- 239000012453 solvate Substances 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 22
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 20
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 17
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 17
- 229910052794 bromium Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 14
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 14
- 201000001881 impotence Diseases 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 13
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 13
- 201000010064 diabetes insipidus Diseases 0.000 claims description 13
- 201000002859 sleep apnea Diseases 0.000 claims description 13
- 230000003542 behavioural effect Effects 0.000 claims description 12
- 208000015114 central nervous system disease Diseases 0.000 claims description 12
- 235000012631 food intake Nutrition 0.000 claims description 12
- 208000006011 Stroke Diseases 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 230000037406 food intake Effects 0.000 claims description 10
- 208000020016 psychiatric disease Diseases 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 230000004064 dysfunction Effects 0.000 claims description 9
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 8
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 8
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 8
- 125000005596 alkyl carboxamido group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000007848 Alcoholism Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 7
- 208000026139 Memory disease Diseases 0.000 claims description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 150000003857 carboxamides Chemical class 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 230000005176 gastrointestinal motility Effects 0.000 claims description 7
- 125000004440 haloalkylsulfinyl group Chemical group 0.000 claims description 7
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000001524 infective effect Effects 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 231100000331 toxic Toxicity 0.000 claims description 7
- 230000002588 toxic effect Effects 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 7
- 230000004584 weight gain Effects 0.000 claims description 7
- 235000019786 weight gain Nutrition 0.000 claims description 7
- DPIBPWQOZUJLSG-UHFFFAOYSA-N 2-ethenyl-1-(3-fluorophenyl)piperazine Chemical compound FC1=CC=CC(N2C(CNCC2)C=C)=C1 DPIBPWQOZUJLSG-UHFFFAOYSA-N 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 208000032841 Bulimia Diseases 0.000 claims description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 6
- 201000009906 Meningitis Diseases 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 208000027626 Neurocognitive disease Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 206010041250 Social phobia Diseases 0.000 claims description 6
- 208000025748 atypical depressive disease Diseases 0.000 claims description 6
- 208000010643 digestive system disease Diseases 0.000 claims description 6
- 206010013663 drug dependence Diseases 0.000 claims description 6
- 206010014599 encephalitis Diseases 0.000 claims description 6
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 6
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 claims description 6
- 201000009941 intracranial hypertension Diseases 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 6
- 208000022821 personality disease Diseases 0.000 claims description 6
- 201000000484 premenstrual tension Diseases 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 230000036186 satiety Effects 0.000 claims description 6
- 235000019627 satiety Nutrition 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- CWXILLBXHNOJHB-UHFFFAOYSA-N 1-(2-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=CC=C1F CWXILLBXHNOJHB-UHFFFAOYSA-N 0.000 claims description 4
- JDXJZFSJPPFAED-UHFFFAOYSA-N 1-(3,5-difluorophenyl)-2-ethenylpiperazine Chemical compound FC1=CC(F)=CC(N2C(CNCC2)C=C)=C1 JDXJZFSJPPFAED-UHFFFAOYSA-N 0.000 claims description 4
- XIBGROAXEIYBKJ-UHFFFAOYSA-N 1-(3,5-difluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(F)=C1 XIBGROAXEIYBKJ-UHFFFAOYSA-N 0.000 claims description 4
- YOOLKLKIUUTLFC-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(Cl)C=C1 YOOLKLKIUUTLFC-UHFFFAOYSA-N 0.000 claims description 4
- XCFHVJJUGCCDJK-UHFFFAOYSA-N 2,4-dimethyl-1-phenylpiperazine Chemical compound CC1CN(C)CCN1C1=CC=CC=C1 XCFHVJJUGCCDJK-UHFFFAOYSA-N 0.000 claims description 4
- RDWOEHNPOCKLRP-UHFFFAOYSA-N 2-methyl-1-(2-methylsulfanylphenyl)piperazine Chemical compound CSC1=CC=CC=C1N1C(C)CNCC1 RDWOEHNPOCKLRP-UHFFFAOYSA-N 0.000 claims description 4
- QDMCWIHRLTVLIY-UHFFFAOYSA-N 2-methyl-1-(3-methylphenyl)piperazine Chemical compound CC1CNCCN1C1=CC=CC(C)=C1 QDMCWIHRLTVLIY-UHFFFAOYSA-N 0.000 claims description 4
- DECNYCSJSYBABP-UHFFFAOYSA-N 2-methyl-1-(4-methylphenyl)piperazine Chemical compound CC1CNCCN1C1=CC=C(C)C=C1 DECNYCSJSYBABP-UHFFFAOYSA-N 0.000 claims description 4
- DCRJYZGRZCZYJZ-UHFFFAOYSA-N 2-methyl-1-phenylpiperazine Chemical compound CC1CNCCN1C1=CC=CC=C1 DCRJYZGRZCZYJZ-UHFFFAOYSA-N 0.000 claims description 4
- XJZKBVHVUWHMFY-UHFFFAOYSA-N 4-(2-methylpiperazin-1-yl)benzamide Chemical compound CC1CNCCN1C1=CC=C(C(N)=O)C=C1 XJZKBVHVUWHMFY-UHFFFAOYSA-N 0.000 claims description 4
- QFDYGAQVIHXBHV-UHFFFAOYSA-N 4-chloro-5-(4-ethyl-2-methylpiperazin-1-yl)-2-nitroaniline Chemical compound CC1CN(CC)CCN1C1=CC(N)=C([N+]([O-])=O)C=C1Cl QFDYGAQVIHXBHV-UHFFFAOYSA-N 0.000 claims description 4
- JOPZGDXGGYEHTE-UHFFFAOYSA-N 4-chloro-5-(4-ethyl-2-methylpiperazin-1-yl)benzene-1,2-diamine Chemical compound CC1CN(CC)CCN1C1=CC(N)=C(N)C=C1Cl JOPZGDXGGYEHTE-UHFFFAOYSA-N 0.000 claims description 4
- CDWUIMQWIVPYDR-MRVPVSSYSA-N (2r)-1-(2,3-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=CC(Cl)=C1Cl CDWUIMQWIVPYDR-MRVPVSSYSA-N 0.000 claims description 3
- JCFNGCGLBWBQHZ-SECBINFHSA-N (2r)-1-(3-chloro-2-methylphenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=CC(Cl)=C1C JCFNGCGLBWBQHZ-SECBINFHSA-N 0.000 claims description 3
- UVYOUTBBJYMAPE-SNVBAGLBSA-N (2r)-1-(5-chloro-2-methylphenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(Cl)=CC=C1C UVYOUTBBJYMAPE-SNVBAGLBSA-N 0.000 claims description 3
- GFJABTPAYSWQOD-QMMMGPOBSA-N (2s)-1-(3-chloro-2-fluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=CC(Cl)=C1F GFJABTPAYSWQOD-QMMMGPOBSA-N 0.000 claims description 3
- JCFNGCGLBWBQHZ-VIFPVBQESA-N (2s)-1-(3-chloro-2-methylphenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=CC(Cl)=C1C JCFNGCGLBWBQHZ-VIFPVBQESA-N 0.000 claims description 3
- DHQGBGMOFXIOBH-QMMMGPOBSA-N (2s)-1-(5-chloro-2-fluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(Cl)=CC=C1F DHQGBGMOFXIOBH-QMMMGPOBSA-N 0.000 claims description 3
- RYKMXBXSDPZIOX-UHFFFAOYSA-N 1-(2,3-difluorophenyl)-2-ethenylpiperazine Chemical compound FC1=CC=CC(N2C(CNCC2)C=C)=C1F RYKMXBXSDPZIOX-UHFFFAOYSA-N 0.000 claims description 3
- CIVITEGEGCFPHG-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-ethylpiperazine Chemical compound CCC1CNCCN1C1=CC=CC(Cl)=C1 CIVITEGEGCFPHG-UHFFFAOYSA-N 0.000 claims description 3
- DJIPSTPEURXLJE-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-ethenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1C(C=C)CNCC1 DJIPSTPEURXLJE-UHFFFAOYSA-N 0.000 claims description 3
- FYMXUKMXSGCIIF-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-ethylpiperazine Chemical compound CCC1CNCCN1C1=CC=C(Cl)C=C1 FYMXUKMXSGCIIF-UHFFFAOYSA-N 0.000 claims description 3
- LSIROHVGZARUJC-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-methylpiperazine Chemical compound C1=CC(OC)=CC=C1N1C(C)CNCC1 LSIROHVGZARUJC-UHFFFAOYSA-N 0.000 claims description 3
- IIJFKTZLTUHMNP-UHFFFAOYSA-N 2-methyl-1-[3-(trifluoromethyl)phenyl]piperazine Chemical compound CC1CNCCN1C1=CC=CC(C(F)(F)F)=C1 IIJFKTZLTUHMNP-UHFFFAOYSA-N 0.000 claims description 3
- HOBUABWUKFNFMD-UHFFFAOYSA-N 4-(2-ethylpiperazin-1-yl)-2-(trifluoromethyl)benzonitrile Chemical compound CCC1CNCCN1C1=CC=C(C#N)C(C(F)(F)F)=C1 HOBUABWUKFNFMD-UHFFFAOYSA-N 0.000 claims description 3
- GGWUVDPHMQZODB-UHFFFAOYSA-N 4-(2-methylpiperazin-1-yl)-2-(trifluoromethyl)benzonitrile Chemical compound CC1CNCCN1C1=CC=C(C#N)C(C(F)(F)F)=C1 GGWUVDPHMQZODB-UHFFFAOYSA-N 0.000 claims description 3
- FRGSPJDDCDBGSM-UHFFFAOYSA-N 5-(4-ethyl-2-methylpiperazin-1-yl)-2-nitro-4-(trifluoromethyl)aniline Chemical compound CC1CN(CC)CCN1C1=CC(N)=C([N+]([O-])=O)C=C1C(F)(F)F FRGSPJDDCDBGSM-UHFFFAOYSA-N 0.000 claims description 3
- LECPZYXTMGQCIE-UHFFFAOYSA-N 5-(4-ethyl-2-methylpiperazin-1-yl)-4-methyl-2-nitroaniline Chemical compound CC1CN(CC)CCN1C1=CC(N)=C([N+]([O-])=O)C=C1C LECPZYXTMGQCIE-UHFFFAOYSA-N 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 238000004260 weight control Methods 0.000 claims description 3
- YXSBPRDHVUGCQV-MRVPVSSYSA-N (2r)-1-(2-chloro-4-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(F)C=C1Cl YXSBPRDHVUGCQV-MRVPVSSYSA-N 0.000 claims description 2
- NGJOHYUVUCMCBI-MRVPVSSYSA-N (2r)-1-(2-chloro-5-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(F)=CC=C1Cl NGJOHYUVUCMCBI-MRVPVSSYSA-N 0.000 claims description 2
- FWVMIKAOFFJLOT-SECBINFHSA-N (2r)-1-(2-chlorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=CC=C1Cl FWVMIKAOFFJLOT-SECBINFHSA-N 0.000 claims description 2
- SHPCZWDRZCWRGW-SNVBAGLBSA-N (2r)-1-(2-fluoro-4-methylphenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(C)C=C1F SHPCZWDRZCWRGW-SNVBAGLBSA-N 0.000 claims description 2
- GTTUADBPLOFPLL-CYBMUJFWSA-N (2r)-1-(2-fluoro-5-phenylphenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(C=2C=CC=CC=2)=CC=C1F GTTUADBPLOFPLL-CYBMUJFWSA-N 0.000 claims description 2
- KWYKEQFSIKSAKJ-MRVPVSSYSA-N (2r)-1-(3,5-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(Cl)=CC(Cl)=C1 KWYKEQFSIKSAKJ-MRVPVSSYSA-N 0.000 claims description 2
- NMAJBBPAZUZNGD-SNVBAGLBSA-N (2r)-1-(3-chloro-4-methylphenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(C)C(Cl)=C1 NMAJBBPAZUZNGD-SNVBAGLBSA-N 0.000 claims description 2
- QSMGVHJDVRQRLZ-SECBINFHSA-N (2r)-1-(3-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=CC(F)=C1 QSMGVHJDVRQRLZ-SECBINFHSA-N 0.000 claims description 2
- RGWQRXKXSCWRNK-SNVBAGLBSA-N (2r)-1-(4-fluoro-2-methylphenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(F)C=C1C RGWQRXKXSCWRNK-SNVBAGLBSA-N 0.000 claims description 2
- LYNYLGWKAUHVMD-SECBINFHSA-N (2r)-1-(4-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(F)C=C1 LYNYLGWKAUHVMD-SECBINFHSA-N 0.000 claims description 2
- DHQGBGMOFXIOBH-MRVPVSSYSA-N (2r)-1-(5-chloro-2-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(Cl)=CC=C1F DHQGBGMOFXIOBH-MRVPVSSYSA-N 0.000 claims description 2
- XDHGGKCNAPCJMP-MRVPVSSYSA-N (2r)-1-[2-fluoro-5-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(C(F)(F)F)=CC=C1F XDHGGKCNAPCJMP-MRVPVSSYSA-N 0.000 claims description 2
- XXZBOXNQPMRDHE-MRVPVSSYSA-N (2r)-1-[3,5-bis(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XXZBOXNQPMRDHE-MRVPVSSYSA-N 0.000 claims description 2
- ZKFMOOPNQZESSI-SNVBAGLBSA-N (2r)-2,4-dimethyl-1-[3-(trifluoromethyl)phenyl]piperazine Chemical compound C[C@@H]1CN(C)CCN1C1=CC=CC(C(F)(F)F)=C1 ZKFMOOPNQZESSI-SNVBAGLBSA-N 0.000 claims description 2
- GDUWSJMPXLBYPG-SECBINFHSA-N (2r)-2-methyl-1-[4-(trifluoromethyl)phenyl]piperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(C(F)(F)F)C=C1 GDUWSJMPXLBYPG-SECBINFHSA-N 0.000 claims description 2
- NXZWNQGGMQTIGU-QMMMGPOBSA-N (2s)-1-(2,4-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(Cl)C=C1Cl NXZWNQGGMQTIGU-QMMMGPOBSA-N 0.000 claims description 2
- FWVMIKAOFFJLOT-VIFPVBQESA-N (2s)-1-(2-chlorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=CC=C1Cl FWVMIKAOFFJLOT-VIFPVBQESA-N 0.000 claims description 2
- SHPCZWDRZCWRGW-JTQLQIEISA-N (2s)-1-(2-fluoro-4-methylphenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(C)C=C1F SHPCZWDRZCWRGW-JTQLQIEISA-N 0.000 claims description 2
- NMAJBBPAZUZNGD-JTQLQIEISA-N (2s)-1-(3-chloro-4-methylphenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(C)C(Cl)=C1 NMAJBBPAZUZNGD-JTQLQIEISA-N 0.000 claims description 2
- QSMGVHJDVRQRLZ-VIFPVBQESA-N (2s)-1-(3-fluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=CC(F)=C1 QSMGVHJDVRQRLZ-VIFPVBQESA-N 0.000 claims description 2
- PZZWVJFHCCPXCR-QMMMGPOBSA-N (2s)-1-(4-chloro-2-fluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(Cl)C=C1F PZZWVJFHCCPXCR-QMMMGPOBSA-N 0.000 claims description 2
- LYNYLGWKAUHVMD-VIFPVBQESA-N (2s)-1-(4-fluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(F)C=C1 LYNYLGWKAUHVMD-VIFPVBQESA-N 0.000 claims description 2
- NFVYBRSFXODFGQ-QMMMGPOBSA-N (2s)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(C(F)(F)F)C=C1F NFVYBRSFXODFGQ-QMMMGPOBSA-N 0.000 claims description 2
- XDHGGKCNAPCJMP-QMMMGPOBSA-N (2s)-1-[2-fluoro-5-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(C(F)(F)F)=CC=C1F XDHGGKCNAPCJMP-QMMMGPOBSA-N 0.000 claims description 2
- XXZBOXNQPMRDHE-QMMMGPOBSA-N (2s)-1-[3,5-bis(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XXZBOXNQPMRDHE-QMMMGPOBSA-N 0.000 claims description 2
- VMOCESUGFYLALB-UHFFFAOYSA-N 1-(2,3-difluorophenyl)-2-ethylpiperazine Chemical compound CCC1CNCCN1C1=CC=CC(F)=C1F VMOCESUGFYLALB-UHFFFAOYSA-N 0.000 claims description 2
- NHTIFWLDYFVRHN-UHFFFAOYSA-N 1-(2-bromo-4-propan-2-ylphenyl)-2-ethenylpiperazine Chemical compound BrC1=CC(C(C)C)=CC=C1N1C(C=C)CNCC1 NHTIFWLDYFVRHN-UHFFFAOYSA-N 0.000 claims description 2
- HVIWMEQXRAFYPH-UHFFFAOYSA-N 1-(2-bromophenyl)-2-ethenylpiperazine Chemical compound BrC1=CC=CC=C1N1C(C=C)CNCC1 HVIWMEQXRAFYPH-UHFFFAOYSA-N 0.000 claims description 2
- ZLZUXQNYUNAYTI-UHFFFAOYSA-N 1-(3-bromophenyl)-2-ethenylpiperazine Chemical compound BrC1=CC=CC(N2C(CNCC2)C=C)=C1 ZLZUXQNYUNAYTI-UHFFFAOYSA-N 0.000 claims description 2
- IWAPFFWHYZQQNO-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-ethenylpiperazine Chemical compound ClC1=CC=CC(N2C(CNCC2)C=C)=C1 IWAPFFWHYZQQNO-UHFFFAOYSA-N 0.000 claims description 2
- KPPRCTGPPHBIJY-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=CC(Cl)=C1 KPPRCTGPPHBIJY-UHFFFAOYSA-N 0.000 claims description 2
- VIUHJEYRGSUXOI-UHFFFAOYSA-N 1-(3-methoxyphenyl)-2-methylpiperazine Chemical compound COC1=CC=CC(N2C(CNCC2)C)=C1 VIUHJEYRGSUXOI-UHFFFAOYSA-N 0.000 claims description 2
- PZZWVJFHCCPXCR-UHFFFAOYSA-N 1-(4-chloro-2-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(Cl)C=C1F PZZWVJFHCCPXCR-UHFFFAOYSA-N 0.000 claims description 2
- ZZGOWKABZUWVJG-UHFFFAOYSA-N 2-ethyl-1-(4-fluorophenyl)piperazine Chemical compound CCC1CNCCN1C1=CC=C(F)C=C1 ZZGOWKABZUWVJG-UHFFFAOYSA-N 0.000 claims description 2
- NXHKKQGYYRVCIL-UHFFFAOYSA-N 3-(2-ethenylpiperazin-1-yl)benzonitrile Chemical compound C=CC1CNCCN1C1=CC=CC(C#N)=C1 NXHKKQGYYRVCIL-UHFFFAOYSA-N 0.000 claims description 2
- XBVHYCCRCQBDBG-MRVPVSSYSA-N (2r)-1-(2,6-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=C(Cl)C=CC=C1Cl XBVHYCCRCQBDBG-MRVPVSSYSA-N 0.000 claims 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 2
- NXZWNQGGMQTIGU-MRVPVSSYSA-N (2r)-1-(2,4-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(Cl)C=C1Cl NXZWNQGGMQTIGU-MRVPVSSYSA-N 0.000 claims 1
- MBYDXRIFXQANNA-SNVBAGLBSA-N (2r)-1-(2-fluoro-5-methylphenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(C)=CC=C1F MBYDXRIFXQANNA-SNVBAGLBSA-N 0.000 claims 1
- JFWWIWQETXDOHR-MRVPVSSYSA-N (2r)-1-[2-chloro-5-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(C(F)(F)F)=CC=C1Cl JFWWIWQETXDOHR-MRVPVSSYSA-N 0.000 claims 1
- YXSBPRDHVUGCQV-QMMMGPOBSA-N (2s)-1-(2-chloro-4-fluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(F)C=C1Cl YXSBPRDHVUGCQV-QMMMGPOBSA-N 0.000 claims 1
- MBYDXRIFXQANNA-JTQLQIEISA-N (2s)-1-(2-fluoro-5-methylphenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(C)=CC=C1F MBYDXRIFXQANNA-JTQLQIEISA-N 0.000 claims 1
- RGWQRXKXSCWRNK-JTQLQIEISA-N (2s)-1-(4-fluoro-2-methylphenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(F)C=C1C RGWQRXKXSCWRNK-JTQLQIEISA-N 0.000 claims 1
- MJMHHRBTVWCAJI-QMMMGPOBSA-N (2s)-1-[2-fluoro-3-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=CC(C(F)(F)F)=C1F MJMHHRBTVWCAJI-QMMMGPOBSA-N 0.000 claims 1
- GDUWSJMPXLBYPG-VIFPVBQESA-N (2s)-2-methyl-1-[4-(trifluoromethyl)phenyl]piperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(C(F)(F)F)C=C1 GDUWSJMPXLBYPG-VIFPVBQESA-N 0.000 claims 1
- WJGWDBUQGYXBAG-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-2-ethylpiperazine Chemical compound CCC1CNCCN1C1=CC=C(F)C(F)=C1 WJGWDBUQGYXBAG-UHFFFAOYSA-N 0.000 claims 1
- IGRGGXLCTSDWAP-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-2-ethenylpiperazine Chemical compound ClC1=CC(Cl)=CC(N2C(CNCC2)C=C)=C1 IGRGGXLCTSDWAP-UHFFFAOYSA-N 0.000 claims 1
- WWQNVJUPRYJNNH-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-2-ethenylpiperazine Chemical compound C1=C(Cl)C(F)=CC=C1N1C(C=C)CNCC1 WWQNVJUPRYJNNH-UHFFFAOYSA-N 0.000 claims 1
- WMBFCHVIYTYEEI-UHFFFAOYSA-N 1-[2-bromo-4-(trifluoromethoxy)phenyl]-2-ethenylpiperazine Chemical compound BrC1=CC(OC(F)(F)F)=CC=C1N1C(C=C)CNCC1 WMBFCHVIYTYEEI-UHFFFAOYSA-N 0.000 claims 1
- HTSNBWHIKCKJPQ-UHFFFAOYSA-N 1-[2-bromo-4-(trifluoromethyl)phenyl]-2-ethenylpiperazine Chemical compound BrC1=CC(C(F)(F)F)=CC=C1N1C(C=C)CNCC1 HTSNBWHIKCKJPQ-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 144
- 238000005481 NMR spectroscopy Methods 0.000 description 116
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 76
- 102000005962 receptors Human genes 0.000 description 75
- 108020003175 receptors Proteins 0.000 description 75
- 239000000543 intermediate Substances 0.000 description 72
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 64
- 239000007787 solid Substances 0.000 description 57
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 45
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 239000012971 dimethylpiperazine Substances 0.000 description 31
- 229940076279 serotonin Drugs 0.000 description 27
- 239000008177 pharmaceutical agent Substances 0.000 description 26
- 239000003112 inhibitor Substances 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 17
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 17
- 101710081950 Xaa-Pro aminopeptidase 2 Proteins 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 235000020825 overweight Nutrition 0.000 description 15
- FMLPQHJYUZTHQS-QMMMGPOBSA-N tert-butyl (3s)-3-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-QMMMGPOBSA-N 0.000 description 15
- 206010033307 Overweight Diseases 0.000 description 14
- 101710121244 Putative Xaa-Pro aminopeptidase Proteins 0.000 description 14
- 101710081951 Xaa-Pro aminopeptidase 1 Proteins 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 229910052722 tritium Inorganic materials 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 208000030814 Eating disease Diseases 0.000 description 12
- 208000019454 Feeding and Eating disease Diseases 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 235000014632 disordered eating Nutrition 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 229940044601 receptor agonist Drugs 0.000 description 12
- 239000000018 receptor agonist Substances 0.000 description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 229940100389 Sulfonylurea Drugs 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000006722 reduction reaction Methods 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 150000003840 hydrochlorides Chemical class 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 7
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 7
- 229940123208 Biguanide Drugs 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 7
- 150000004283 biguanides Chemical class 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 229950004994 meglitinide Drugs 0.000 description 7
- 230000018052 penile erection Effects 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 239000005541 ACE inhibitor Substances 0.000 description 6
- 208000037259 Amyloid Plaque Diseases 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 6
- 239000000883 anti-obesity agent Substances 0.000 description 6
- 229940125710 antiobesity agent Drugs 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- MLBHFBKZUPLWBD-ZETCQYMHSA-N (2S)-1-[3-(trifluoromethyl)phenyl]-2-propanamine Chemical compound C[C@H](N)CC1=CC=CC(C(F)(F)F)=C1 MLBHFBKZUPLWBD-ZETCQYMHSA-N 0.000 description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 5
- 239000002830 appetite depressant Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 5
- 229960001243 orlistat Drugs 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000003614 peroxisome proliferator Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 5
- 229960004425 sibutramine Drugs 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- DXJOJUNLMJMJSN-UHFFFAOYSA-N tert-butyl 3-ethylpiperazine-1-carboxylate Chemical compound CCC1CN(C(=O)OC(C)(C)C)CCN1 DXJOJUNLMJMJSN-UHFFFAOYSA-N 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 4
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 201000001883 cholelithiasis Diseases 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229940031439 squalene Drugs 0.000 description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QJFFHGINEPHZKD-MRVPVSSYSA-N (2r)-1-(3,4-difluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(F)C(F)=C1 QJFFHGINEPHZKD-MRVPVSSYSA-N 0.000 description 3
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 3
- NHDODQWIKUYWMW-UHFFFAOYSA-N 1-bromo-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C=C1 NHDODQWIKUYWMW-UHFFFAOYSA-N 0.000 description 3
- CJTIWGBQCVYTQE-UHFFFAOYSA-N 4-bromo-2-chloro-1-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1Cl CJTIWGBQCVYTQE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000011690 Adiponectin Human genes 0.000 description 3
- 108010076365 Adiponectin Proteins 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 3
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920001268 Cholestyramine Polymers 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 229920002911 Colestipol Polymers 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940125709 anorectic agent Drugs 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 229960000516 bezafibrate Drugs 0.000 description 3
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 3
- 229920000080 bile acid sequestrant Polymers 0.000 description 3
- 229940096699 bile acid sequestrants Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 208000014679 binge eating disease Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 3
- 229960002802 bromocriptine Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 229960001214 clofibrate Drugs 0.000 description 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 3
- 229960003009 clopidogrel Drugs 0.000 description 3
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 3
- 229960002604 colestipol Drugs 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229960002297 fenofibrate Drugs 0.000 description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229960003627 gemfibrozil Drugs 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical class O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 230000000436 pro-erectile effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000719 purinergic P2Y receptor antagonist Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 3
- 229960005001 ticlopidine Drugs 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- YRIYHVHGFCRQOS-MRVPVSSYSA-N (2r)-1-(2,5-difluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(F)=CC=C1F YRIYHVHGFCRQOS-MRVPVSSYSA-N 0.000 description 2
- AFTBQJJLLPXPBW-DDWIOCJRSA-N (2r)-1-(3,4-difluorophenyl)-2-methylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@@H]1CNCCN1C1=CC=C(F)C(F)=C1 AFTBQJJLLPXPBW-DDWIOCJRSA-N 0.000 description 2
- GFJABTPAYSWQOD-MRVPVSSYSA-N (2r)-1-(3-chloro-2-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=CC(Cl)=C1F GFJABTPAYSWQOD-MRVPVSSYSA-N 0.000 description 2
- NOBBTCFLCFDHMF-DDWIOCJRSA-N (2r)-1-(3-chloro-5-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC(F)=CC(Cl)=C1 NOBBTCFLCFDHMF-DDWIOCJRSA-N 0.000 description 2
- VNFJVUAMNMWJRT-MRVPVSSYSA-N (2r)-1-(4-chloro-3-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(Cl)C(F)=C1 VNFJVUAMNMWJRT-MRVPVSSYSA-N 0.000 description 2
- GQXWSTBYCKHIDY-SNVBAGLBSA-N (2r)-1-(5-chloro-2-fluorophenyl)-2-ethylpiperazine Chemical compound CC[C@@H]1CNCCN1C1=CC(Cl)=CC=C1F GQXWSTBYCKHIDY-SNVBAGLBSA-N 0.000 description 2
- YRIYHVHGFCRQOS-QMMMGPOBSA-N (2s)-1-(2,5-difluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(F)=CC=C1F YRIYHVHGFCRQOS-QMMMGPOBSA-N 0.000 description 2
- ZICABQASCKEIKA-JTQLQIEISA-N (2s)-1-(2-fluorophenyl)-2,4-dimethylpiperazine Chemical compound C[C@H]1CN(C)CCN1C1=CC=CC=C1F ZICABQASCKEIKA-JTQLQIEISA-N 0.000 description 2
- QJFFHGINEPHZKD-QMMMGPOBSA-N (2s)-1-(3,4-difluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(F)C(F)=C1 QJFFHGINEPHZKD-QMMMGPOBSA-N 0.000 description 2
- YMJWGZKAJRVNBY-QRPNPIFTSA-N (2s)-1-(3,4-difluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(F)C(F)=C1 YMJWGZKAJRVNBY-QRPNPIFTSA-N 0.000 description 2
- KWYKEQFSIKSAKJ-QMMMGPOBSA-N (2s)-1-(3,5-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(Cl)=CC(Cl)=C1 KWYKEQFSIKSAKJ-QMMMGPOBSA-N 0.000 description 2
- UVYOUTBBJYMAPE-JTQLQIEISA-N (2s)-1-(5-chloro-2-methylphenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(Cl)=CC=C1C UVYOUTBBJYMAPE-JTQLQIEISA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- QTBXIDJGFJJBQZ-UHFFFAOYSA-N 1-(2-bromo-4-propan-2-ylphenyl)-2-ethenylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.BrC1=CC(C(C)C)=CC=C1N1C(C=C)CNCC1 QTBXIDJGFJJBQZ-UHFFFAOYSA-N 0.000 description 2
- NWAIPBTWJTWNMD-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-2-ethenylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.ClC1=CC(Cl)=CC(N2C(CNCC2)C=C)=C1 NWAIPBTWJTWNMD-UHFFFAOYSA-N 0.000 description 2
- DSJKWQCDVHUQLY-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(F)C(Cl)=C1 DSJKWQCDVHUQLY-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- ZGUYBBJFYJFUNK-UHFFFAOYSA-N 1-[2-bromo-4-(trifluoromethyl)phenyl]-2-ethenylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.BrC1=CC(C(F)(F)F)=CC=C1N1C(C=C)CNCC1 ZGUYBBJFYJFUNK-UHFFFAOYSA-N 0.000 description 2
- DZHFFMWJXJBBRG-UHFFFAOYSA-N 1-bromo-3,5-dichlorobenzene Chemical compound ClC1=CC(Cl)=CC(Br)=C1 DZHFFMWJXJBBRG-UHFFFAOYSA-N 0.000 description 2
- DMARBQGIQKLIPM-UHFFFAOYSA-N 1-bromo-3-chloro-2-methylbenzene Chemical compound CC1=C(Cl)C=CC=C1Br DMARBQGIQKLIPM-UHFFFAOYSA-N 0.000 description 2
- AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 2
- DCRYNQTXGUTACA-UHFFFAOYSA-N 1-ethenylpiperazine Chemical compound C=CN1CCNCC1 DCRYNQTXGUTACA-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- XCRCSPKQEDMVBO-UHFFFAOYSA-N 2-bromo-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(Br)=C1 XCRCSPKQEDMVBO-UHFFFAOYSA-N 0.000 description 2
- YFFUYGSLQXVHMB-UHFFFAOYSA-N 2-bromo-4-chloro-1-fluorobenzene Chemical compound FC1=CC=C(Cl)C=C1Br YFFUYGSLQXVHMB-UHFFFAOYSA-N 0.000 description 2
- CSUUXPHPCXHYGY-UHFFFAOYSA-N 2-bromo-4-chloro-1-methylbenzene Chemical compound CC1=CC=C(Cl)C=C1Br CSUUXPHPCXHYGY-UHFFFAOYSA-N 0.000 description 2
- IXHWPYBCIPTZJW-UHFFFAOYSA-N 2-ethyl-1-(4-fluorophenyl)piperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCC1CNCCN1C1=CC=C(F)C=C1 IXHWPYBCIPTZJW-UHFFFAOYSA-N 0.000 description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- DEMRDCVRJRHSPX-UHFFFAOYSA-N 3-(2-methylpiperazin-1-yl)benzonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1CNCCN1C1=CC=CC(C#N)=C1 DEMRDCVRJRHSPX-UHFFFAOYSA-N 0.000 description 2
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 2
- OBMBCPDCBAQOMA-UHFFFAOYSA-N 4-(2-methylpiperazin-1-yl)phenol Chemical compound CC1CNCCN1C1=CC=C(O)C=C1 OBMBCPDCBAQOMA-UHFFFAOYSA-N 0.000 description 2
- IIAFJSQJJJZCIF-UHFFFAOYSA-N 4-(2-propan-2-ylpiperazin-1-yl)-2-(trifluoromethyl)benzonitrile Chemical compound CC(C)C1CNCCN1C1=CC=C(C#N)C(C(F)(F)F)=C1 IIAFJSQJJJZCIF-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- LURUFFRBWBVAPA-UHFFFAOYSA-N 4-amino-3-fluoro-2-(2-methylpiperazin-1-yl)-5-nitrobenzonitrile Chemical compound CC1CNCCN1C1=C(F)C(N)=C([N+]([O-])=O)C=C1C#N LURUFFRBWBVAPA-UHFFFAOYSA-N 0.000 description 2
- CFPZDVAZISWERM-UHFFFAOYSA-N 4-bromo-1,2-dichlorobenzene Chemical compound ClC1=CC=C(Br)C=C1Cl CFPZDVAZISWERM-UHFFFAOYSA-N 0.000 description 2
- AGYWDGVTLKNTBS-UHFFFAOYSA-N 4-bromo-1-chloro-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1Cl AGYWDGVTLKNTBS-UHFFFAOYSA-N 0.000 description 2
- LIFMTDJMLRECMX-UHFFFAOYSA-N 4-bromo-2-chloro-1-methylbenzene Chemical compound CC1=CC=C(Br)C=C1Cl LIFMTDJMLRECMX-UHFFFAOYSA-N 0.000 description 2
- 229940124596 AChE inhibitor Drugs 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010235 Food Addiction Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229940122199 Insulin secretagogue Drugs 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- 206010028403 Mutism Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 206010029897 Obsessive thoughts Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 2
- 102400000472 Sucrase Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102100038364 Xaa-Pro aminopeptidase 2 Human genes 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000001509 acute urate nephropathy Diseases 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000000578 anorexic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 230000001856 erectile effect Effects 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 229960000815 ezetimibe Drugs 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000019525 fullness Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 150000002576 ketones Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002596 lactones Chemical group 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- IUELCJNBXSHUDO-UHFFFAOYSA-N n-(2-bromoethyl)-2-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)NCCBr IUELCJNBXSHUDO-UHFFFAOYSA-N 0.000 description 2
- GOUPBHNIKNHXDF-UHFFFAOYSA-N n-[2-(2-bromoanilino)ethyl]-2-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)NCCNC1=CC=CC=C1Br GOUPBHNIKNHXDF-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 208000001797 obstructive sleep apnea Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- MZMOYVCDPQCUOP-UHFFFAOYSA-N piperazin-1-ium;2,2,2-trifluoroacetate Chemical compound C1C[NH2+]CCN1.[O-]C(=O)C(F)(F)F MZMOYVCDPQCUOP-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
- 229960003908 pseudoephedrine Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000009933 reproductive health Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000006965 reversible inhibition Effects 0.000 description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000022170 stress incontinence Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 208000019808 uric acid nephrolithiasis Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- VXEVKSKAINMPFG-QWUNSSNDSA-N (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-4-carboxy-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-(carboxymethylamino)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-hydroxypentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CNC=N6)N)O)C(=O)O VXEVKSKAINMPFG-QWUNSSNDSA-N 0.000 description 1
- GDNGMSCFDVPSOB-SBSPUUFOSA-N (2r)-1-(2,3-dichlorophenyl)-2,4-dimethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@@H]1CN(C)CCN1C1=CC=CC(Cl)=C1Cl GDNGMSCFDVPSOB-SBSPUUFOSA-N 0.000 description 1
- RYKMXBXSDPZIOX-SECBINFHSA-N (2r)-1-(2,3-difluorophenyl)-2-ethenylpiperazine Chemical compound FC1=CC=CC(N2[C@@H](CNCC2)C=C)=C1F RYKMXBXSDPZIOX-SECBINFHSA-N 0.000 description 1
- VMOCESUGFYLALB-SECBINFHSA-N (2r)-1-(2,3-difluorophenyl)-2-ethylpiperazine Chemical compound CC[C@@H]1CNCCN1C1=CC=CC(F)=C1F VMOCESUGFYLALB-SECBINFHSA-N 0.000 description 1
- KQOFHOCCLFSRHP-DDWIOCJRSA-N (2r)-1-(2,5-dichlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC(Cl)=CC=C1Cl KQOFHOCCLFSRHP-DDWIOCJRSA-N 0.000 description 1
- WVBDALRAACLXHH-MRVPVSSYSA-N (2r)-1-(2,5-difluoro-4-methoxyphenyl)-2-methylpiperazine Chemical compound C1=C(F)C(OC)=CC(F)=C1N1[C@H](C)CNCC1 WVBDALRAACLXHH-MRVPVSSYSA-N 0.000 description 1
- BYTNATOVOUXHEI-DDWIOCJRSA-N (2r)-1-(2,5-difluoro-4-methoxyphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C1=C(F)C(OC)=CC(F)=C1N1[C@H](C)CNCC1 BYTNATOVOUXHEI-DDWIOCJRSA-N 0.000 description 1
- IKSXNYOHGVGCAH-DDWIOCJRSA-N (2r)-1-(2,6-dichlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=C(Cl)C=CC=C1Cl IKSXNYOHGVGCAH-DDWIOCJRSA-N 0.000 description 1
- HVIWMEQXRAFYPH-SNVBAGLBSA-N (2r)-1-(2-bromophenyl)-2-ethenylpiperazine Chemical compound BrC1=CC=CC=C1N1[C@H](C=C)CNCC1 HVIWMEQXRAFYPH-SNVBAGLBSA-N 0.000 description 1
- OZCOMOGNSHFBAU-MRVPVSSYSA-N (2r)-1-(2-chloro-3-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=CC(F)=C1Cl OZCOMOGNSHFBAU-MRVPVSSYSA-N 0.000 description 1
- GSJNFMOCKNYRPJ-DDWIOCJRSA-N (2r)-1-(2-chloro-3-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=CC(F)=C1Cl GSJNFMOCKNYRPJ-DDWIOCJRSA-N 0.000 description 1
- WTFMLKWWPOXPOA-DDWIOCJRSA-N (2r)-1-(2-chloro-4-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(F)C=C1Cl WTFMLKWWPOXPOA-DDWIOCJRSA-N 0.000 description 1
- QSRUHIJCWPMWTO-DDWIOCJRSA-N (2r)-1-(2-chloro-5-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC(F)=CC=C1Cl QSRUHIJCWPMWTO-DDWIOCJRSA-N 0.000 description 1
- FCLDVDMZYPDJII-SBSPUUFOSA-N (2r)-1-(2-chlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=CC=C1Cl FCLDVDMZYPDJII-SBSPUUFOSA-N 0.000 description 1
- WBRMJKLMJAGRON-HNCPQSOCSA-N (2r)-1-(2-fluoro-4-methylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(C)C=C1F WBRMJKLMJAGRON-HNCPQSOCSA-N 0.000 description 1
- HTPTUKRRRFECLJ-HNCPQSOCSA-N (2r)-1-(2-fluoro-5-methylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC(C)=CC=C1F HTPTUKRRRFECLJ-HNCPQSOCSA-N 0.000 description 1
- ZIMYEFRODSRMQC-SBSPUUFOSA-N (2r)-1-(2-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=CC=C1F ZIMYEFRODSRMQC-SBSPUUFOSA-N 0.000 description 1
- ABBYYKOVPBRUEE-MRVPVSSYSA-N (2r)-1-(3,4-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(Cl)C(Cl)=C1 ABBYYKOVPBRUEE-MRVPVSSYSA-N 0.000 description 1
- IWDRYXJXBYSZDK-DDWIOCJRSA-N (2r)-1-(3,4-dichlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(Cl)C(Cl)=C1 IWDRYXJXBYSZDK-DDWIOCJRSA-N 0.000 description 1
- WJGWDBUQGYXBAG-SECBINFHSA-N (2r)-1-(3,4-difluorophenyl)-2-ethylpiperazine Chemical compound CC[C@@H]1CNCCN1C1=CC=C(F)C(F)=C1 WJGWDBUQGYXBAG-SECBINFHSA-N 0.000 description 1
- VMZFRTOOGRQIRQ-SBSPUUFOSA-N (2r)-1-(3,5-dichlorophenyl)-2,4-dimethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@@H]1CN(C)CCN1C1=CC(Cl)=CC(Cl)=C1 VMZFRTOOGRQIRQ-SBSPUUFOSA-N 0.000 description 1
- IGRGGXLCTSDWAP-LLVKDONJSA-N (2r)-1-(3,5-dichlorophenyl)-2-ethenylpiperazine Chemical compound ClC1=CC(Cl)=CC(N2[C@@H](CNCC2)C=C)=C1 IGRGGXLCTSDWAP-LLVKDONJSA-N 0.000 description 1
- OQHBVUJGDPKAFS-DDWIOCJRSA-N (2r)-1-(3,5-dichlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC(Cl)=CC(Cl)=C1 OQHBVUJGDPKAFS-DDWIOCJRSA-N 0.000 description 1
- JDXJZFSJPPFAED-LLVKDONJSA-N (2r)-1-(3,5-difluorophenyl)-2-ethenylpiperazine Chemical compound FC1=CC(F)=CC(N2[C@@H](CNCC2)C=C)=C1 JDXJZFSJPPFAED-LLVKDONJSA-N 0.000 description 1
- XIBGROAXEIYBKJ-MRVPVSSYSA-N (2r)-1-(3,5-difluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(F)=CC(F)=C1 XIBGROAXEIYBKJ-MRVPVSSYSA-N 0.000 description 1
- ZLZUXQNYUNAYTI-LLVKDONJSA-N (2r)-1-(3-bromophenyl)-2-ethenylpiperazine Chemical compound BrC1=CC=CC(N2[C@@H](CNCC2)C=C)=C1 ZLZUXQNYUNAYTI-LLVKDONJSA-N 0.000 description 1
- VBOVHYSJNOMDLI-DDWIOCJRSA-N (2r)-1-(3-chloro-2-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=CC(Cl)=C1F VBOVHYSJNOMDLI-DDWIOCJRSA-N 0.000 description 1
- HECNTEPHSACHDE-SBSPUUFOSA-N (2r)-1-(3-chloro-2-methylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=CC(Cl)=C1C HECNTEPHSACHDE-SBSPUUFOSA-N 0.000 description 1
- WWQNVJUPRYJNNH-SECBINFHSA-N (2r)-1-(3-chloro-4-fluorophenyl)-2-ethenylpiperazine Chemical compound C1=C(Cl)C(F)=CC=C1N1[C@H](C=C)CNCC1 WWQNVJUPRYJNNH-SECBINFHSA-N 0.000 description 1
- FHUJWWNZPVLGKR-SECBINFHSA-N (2r)-1-(3-chloro-4-fluorophenyl)-2-ethylpiperazine Chemical compound CC[C@@H]1CNCCN1C1=CC=C(F)C(Cl)=C1 FHUJWWNZPVLGKR-SECBINFHSA-N 0.000 description 1
- OTCDXKODTDLOAP-DDWIOCJRSA-N (2r)-1-(3-chloro-4-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(F)C(Cl)=C1 OTCDXKODTDLOAP-DDWIOCJRSA-N 0.000 description 1
- NQHOSLDPCAFJLV-HNCPQSOCSA-N (2r)-1-(3-chloro-4-methylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(C)C(Cl)=C1 NQHOSLDPCAFJLV-HNCPQSOCSA-N 0.000 description 1
- ZXBWCAVSVDIMSH-MRVPVSSYSA-N (2r)-1-(3-chloro-5-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC(F)=CC(Cl)=C1 ZXBWCAVSVDIMSH-MRVPVSSYSA-N 0.000 description 1
- ZXRUEMXTLXAHCI-HNCPQSOCSA-N (2r)-1-(3-chlorophenyl)-2,4-dimethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@@H]1CN(C)CCN1C1=CC=CC(Cl)=C1 ZXRUEMXTLXAHCI-HNCPQSOCSA-N 0.000 description 1
- IWAPFFWHYZQQNO-LLVKDONJSA-N (2r)-1-(3-chlorophenyl)-2-ethenylpiperazine Chemical compound ClC1=CC=CC(N2[C@@H](CNCC2)C=C)=C1 IWAPFFWHYZQQNO-LLVKDONJSA-N 0.000 description 1
- BOMBMAWLTMFIQD-SBSPUUFOSA-N (2r)-1-(3-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=CC(F)=C1 BOMBMAWLTMFIQD-SBSPUUFOSA-N 0.000 description 1
- PZZWVJFHCCPXCR-MRVPVSSYSA-N (2r)-1-(4-chloro-2-fluorophenyl)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(Cl)C=C1F PZZWVJFHCCPXCR-MRVPVSSYSA-N 0.000 description 1
- VFONQSOGOVFAMO-DDWIOCJRSA-N (2r)-1-(4-chloro-2-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(Cl)C=C1F VFONQSOGOVFAMO-DDWIOCJRSA-N 0.000 description 1
- KLERMMYBVDMDQN-DDWIOCJRSA-N (2r)-1-(4-chloro-3-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(Cl)C(F)=C1 KLERMMYBVDMDQN-DDWIOCJRSA-N 0.000 description 1
- FYMXUKMXSGCIIF-LLVKDONJSA-N (2r)-1-(4-chlorophenyl)-2-ethylpiperazine Chemical compound CC[C@@H]1CNCCN1C1=CC=C(Cl)C=C1 FYMXUKMXSGCIIF-LLVKDONJSA-N 0.000 description 1
- FVAIAHKDGNTVEO-SBSPUUFOSA-N (2r)-1-(4-chlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(Cl)C=C1 FVAIAHKDGNTVEO-SBSPUUFOSA-N 0.000 description 1
- FJOYIXRNRCSMGN-LLVKDONJSA-N (2r)-1-(4-fluoro-2-methylphenyl)-2,4-dimethylpiperazine Chemical compound C[C@@H]1CN(C)CCN1C1=CC=C(F)C=C1C FJOYIXRNRCSMGN-LLVKDONJSA-N 0.000 description 1
- ZWKYZCYABZNHGL-HNCPQSOCSA-N (2r)-1-(4-fluoro-2-methylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(F)C=C1C ZWKYZCYABZNHGL-HNCPQSOCSA-N 0.000 description 1
- HPRDTDBBKORMMA-SBSPUUFOSA-N (2r)-1-(4-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(F)C=C1 HPRDTDBBKORMMA-SBSPUUFOSA-N 0.000 description 1
- ONXUKTSFWJTCDE-SECBINFHSA-N (2r)-1-(5-chloro-2-fluorophenyl)-2,4-dimethylpiperazine Chemical compound C[C@@H]1CN(C)CCN1C1=CC(Cl)=CC=C1F ONXUKTSFWJTCDE-SECBINFHSA-N 0.000 description 1
- PTVUXOIVYHLVTP-SBSPUUFOSA-N (2r)-1-(5-chloro-2-fluorophenyl)-2,4-dimethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@@H]1CN(C)CCN1C1=CC(Cl)=CC=C1F PTVUXOIVYHLVTP-SBSPUUFOSA-N 0.000 description 1
- XGVVXDUXZXGYHY-HNCPQSOCSA-N (2r)-1-(5-chloro-2-methylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC(Cl)=CC=C1C XGVVXDUXZXGYHY-HNCPQSOCSA-N 0.000 description 1
- WMBFCHVIYTYEEI-SECBINFHSA-N (2r)-1-[2-bromo-4-(trifluoromethoxy)phenyl]-2-ethenylpiperazine Chemical compound BrC1=CC(OC(F)(F)F)=CC=C1N1[C@H](C=C)CNCC1 WMBFCHVIYTYEEI-SECBINFHSA-N 0.000 description 1
- HCDHRWANLGCEPT-SBSPUUFOSA-N (2r)-1-[2-chloro-5-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@@H]1CN(C)CCN1C1=CC(C(F)(F)F)=CC=C1Cl HCDHRWANLGCEPT-SBSPUUFOSA-N 0.000 description 1
- GYHYPTILYXWUPH-SECBINFHSA-N (2r)-1-[2-fluoro-3-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound C[C@@H]1CN(C)CCN1C1=CC=CC(C(F)(F)F)=C1F GYHYPTILYXWUPH-SECBINFHSA-N 0.000 description 1
- MJMHHRBTVWCAJI-MRVPVSSYSA-N (2r)-1-[2-fluoro-3-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=CC(C(F)(F)F)=C1F MJMHHRBTVWCAJI-MRVPVSSYSA-N 0.000 description 1
- FASFHBDEESFVEB-DDWIOCJRSA-N (2r)-1-[2-fluoro-3-(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=CC(C(F)(F)F)=C1F FASFHBDEESFVEB-DDWIOCJRSA-N 0.000 description 1
- ZNUHBLZOZVNUJL-SECBINFHSA-N (2r)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound C[C@@H]1CN(C)CCN1C1=CC=C(C(F)(F)F)C=C1F ZNUHBLZOZVNUJL-SECBINFHSA-N 0.000 description 1
- LKWJIUWNAZXCSU-DDWIOCJRSA-N (2r)-1-[2-fluoro-5-(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC(C(F)(F)F)=CC=C1F LKWJIUWNAZXCSU-DDWIOCJRSA-N 0.000 description 1
- WHTSMYGJJMMKBA-SECBINFHSA-N (2r)-1-[3,5-bis(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound C[C@@H]1CN(C)CCN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WHTSMYGJJMMKBA-SECBINFHSA-N 0.000 description 1
- VTLAOTMNWKZTPV-DDWIOCJRSA-N (2r)-1-[3,5-bis(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VTLAOTMNWKZTPV-DDWIOCJRSA-N 0.000 description 1
- BWCOZNJHAUBKKF-DDWIOCJRSA-N (2r)-1-[3-fluoro-5-(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC(F)=CC(C(F)(F)F)=C1 BWCOZNJHAUBKKF-DDWIOCJRSA-N 0.000 description 1
- LOOZOOYWWZXXCP-SECBINFHSA-N (2r)-1-[4-chloro-3-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound C[C@@H]1CN(C)CCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 LOOZOOYWWZXXCP-SECBINFHSA-N 0.000 description 1
- UMPVEZIMGWSIBK-MRVPVSSYSA-N (2r)-1-[4-chloro-3-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 UMPVEZIMGWSIBK-MRVPVSSYSA-N 0.000 description 1
- RPQORAHULCDLHN-DDWIOCJRSA-N (2r)-1-[4-chloro-3-(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 RPQORAHULCDLHN-DDWIOCJRSA-N 0.000 description 1
- IJFZUAZLNPWATO-HNCPQSOCSA-N (2r)-2,4-dimethyl-1-[3-(trifluoromethyl)phenyl]piperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@@H]1CN(C)CCN1C1=CC=CC(C(F)(F)F)=C1 IJFZUAZLNPWATO-HNCPQSOCSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- DPIBPWQOZUJLSG-LLVKDONJSA-N (2r)-2-ethenyl-1-(3-fluorophenyl)piperazine Chemical compound FC1=CC=CC(N2[C@@H](CNCC2)C=C)=C1 DPIBPWQOZUJLSG-LLVKDONJSA-N 0.000 description 1
- ZZGOWKABZUWVJG-LLVKDONJSA-N (2r)-2-ethyl-1-(4-fluorophenyl)piperazine Chemical compound CC[C@@H]1CNCCN1C1=CC=C(F)C=C1 ZZGOWKABZUWVJG-LLVKDONJSA-N 0.000 description 1
- MXXIBFCOQJFCCL-SBSPUUFOSA-N (2r)-2-methyl-1-[3-(trifluoromethyl)phenyl]piperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=CC(C(F)(F)F)=C1 MXXIBFCOQJFCCL-SBSPUUFOSA-N 0.000 description 1
- MKOVSSQUDMAZFE-SBSPUUFOSA-N (2r)-2-methyl-1-[4-(trifluoromethyl)phenyl]piperazine;hydrochloride Chemical compound Cl.C[C@@H]1CNCCN1C1=CC=C(C(F)(F)F)C=C1 MKOVSSQUDMAZFE-SBSPUUFOSA-N 0.000 description 1
- CDWUIMQWIVPYDR-QMMMGPOBSA-N (2s)-1-(2,3-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=CC(Cl)=C1Cl CDWUIMQWIVPYDR-QMMMGPOBSA-N 0.000 description 1
- RJAXSGRBYNGSBD-QRPNPIFTSA-N (2s)-1-(2,3-dichlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=CC(Cl)=C1Cl RJAXSGRBYNGSBD-QRPNPIFTSA-N 0.000 description 1
- RYKMXBXSDPZIOX-VIFPVBQESA-N (2s)-1-(2,3-difluorophenyl)-2-ethenylpiperazine Chemical compound FC1=CC=CC(N2[C@H](CNCC2)C=C)=C1F RYKMXBXSDPZIOX-VIFPVBQESA-N 0.000 description 1
- VMOCESUGFYLALB-VIFPVBQESA-N (2s)-1-(2,3-difluorophenyl)-2-ethylpiperazine Chemical compound CC[C@H]1CNCCN1C1=CC=CC(F)=C1F VMOCESUGFYLALB-VIFPVBQESA-N 0.000 description 1
- YDBYTOUVQPIUTM-QRPNPIFTSA-N (2s)-1-(2,4-dichlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(Cl)C=C1Cl YDBYTOUVQPIUTM-QRPNPIFTSA-N 0.000 description 1
- SCEDANZPTHLNNQ-QMMMGPOBSA-N (2s)-1-(2,5-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(Cl)=CC=C1Cl SCEDANZPTHLNNQ-QMMMGPOBSA-N 0.000 description 1
- FVRNKHODHPIKCU-QRPNPIFTSA-N (2s)-1-(2,5-difluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC(F)=CC=C1F FVRNKHODHPIKCU-QRPNPIFTSA-N 0.000 description 1
- IKSXNYOHGVGCAH-QRPNPIFTSA-N (2s)-1-(2,6-dichlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=C(Cl)C=CC=C1Cl IKSXNYOHGVGCAH-QRPNPIFTSA-N 0.000 description 1
- NHTIFWLDYFVRHN-ZDUSSCGKSA-N (2s)-1-(2-bromo-4-propan-2-ylphenyl)-2-ethenylpiperazine Chemical compound BrC1=CC(C(C)C)=CC=C1N1[C@@H](C=C)CNCC1 NHTIFWLDYFVRHN-ZDUSSCGKSA-N 0.000 description 1
- WTFMLKWWPOXPOA-QRPNPIFTSA-N (2s)-1-(2-chloro-4-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(F)C=C1Cl WTFMLKWWPOXPOA-QRPNPIFTSA-N 0.000 description 1
- FCLDVDMZYPDJII-FVGYRXGTSA-N (2s)-1-(2-chlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=CC=C1Cl FCLDVDMZYPDJII-FVGYRXGTSA-N 0.000 description 1
- WBRMJKLMJAGRON-PPHPATTJSA-N (2s)-1-(2-fluoro-4-methylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(C)C=C1F WBRMJKLMJAGRON-PPHPATTJSA-N 0.000 description 1
- GTTUADBPLOFPLL-ZDUSSCGKSA-N (2s)-1-(2-fluoro-5-phenylphenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(C=2C=CC=CC=2)=CC=C1F GTTUADBPLOFPLL-ZDUSSCGKSA-N 0.000 description 1
- TXYSYEHKIQQAKV-ZOWNYOTGSA-N (2s)-1-(2-fluoro-5-phenylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC(C=2C=CC=CC=2)=CC=C1F TXYSYEHKIQQAKV-ZOWNYOTGSA-N 0.000 description 1
- ZIMYEFRODSRMQC-FVGYRXGTSA-N (2s)-1-(2-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=CC=C1F ZIMYEFRODSRMQC-FVGYRXGTSA-N 0.000 description 1
- ABBYYKOVPBRUEE-QMMMGPOBSA-N (2s)-1-(3,4-dichlorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(Cl)C(Cl)=C1 ABBYYKOVPBRUEE-QMMMGPOBSA-N 0.000 description 1
- IWDRYXJXBYSZDK-QRPNPIFTSA-N (2s)-1-(3,4-dichlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(Cl)C(Cl)=C1 IWDRYXJXBYSZDK-QRPNPIFTSA-N 0.000 description 1
- WJGWDBUQGYXBAG-VIFPVBQESA-N (2s)-1-(3,4-difluorophenyl)-2-ethylpiperazine Chemical compound CC[C@H]1CNCCN1C1=CC=C(F)C(F)=C1 WJGWDBUQGYXBAG-VIFPVBQESA-N 0.000 description 1
- IGRGGXLCTSDWAP-NSHDSACASA-N (2s)-1-(3,5-dichlorophenyl)-2-ethenylpiperazine Chemical compound ClC1=CC(Cl)=CC(N2[C@H](CNCC2)C=C)=C1 IGRGGXLCTSDWAP-NSHDSACASA-N 0.000 description 1
- OQHBVUJGDPKAFS-QRPNPIFTSA-N (2s)-1-(3,5-dichlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC(Cl)=CC(Cl)=C1 OQHBVUJGDPKAFS-QRPNPIFTSA-N 0.000 description 1
- JDXJZFSJPPFAED-NSHDSACASA-N (2s)-1-(3,5-difluorophenyl)-2-ethenylpiperazine Chemical compound FC1=CC(F)=CC(N2[C@H](CNCC2)C=C)=C1 JDXJZFSJPPFAED-NSHDSACASA-N 0.000 description 1
- XIBGROAXEIYBKJ-QMMMGPOBSA-N (2s)-1-(3,5-difluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(F)=CC(F)=C1 XIBGROAXEIYBKJ-QMMMGPOBSA-N 0.000 description 1
- ORBPIQKDFIVTKH-QRPNPIFTSA-N (2s)-1-(3,5-difluorophenyl)-2-methylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H]1CNCCN1C1=CC(F)=CC(F)=C1 ORBPIQKDFIVTKH-QRPNPIFTSA-N 0.000 description 1
- ZLZUXQNYUNAYTI-NSHDSACASA-N (2s)-1-(3-bromophenyl)-2-ethenylpiperazine Chemical compound BrC1=CC=CC(N2[C@H](CNCC2)C=C)=C1 ZLZUXQNYUNAYTI-NSHDSACASA-N 0.000 description 1
- VBOVHYSJNOMDLI-QRPNPIFTSA-N (2s)-1-(3-chloro-2-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=CC(Cl)=C1F VBOVHYSJNOMDLI-QRPNPIFTSA-N 0.000 description 1
- HECNTEPHSACHDE-FVGYRXGTSA-N (2s)-1-(3-chloro-2-methylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=CC(Cl)=C1C HECNTEPHSACHDE-FVGYRXGTSA-N 0.000 description 1
- FHUJWWNZPVLGKR-VIFPVBQESA-N (2s)-1-(3-chloro-4-fluorophenyl)-2-ethylpiperazine Chemical compound CC[C@H]1CNCCN1C1=CC=C(F)C(Cl)=C1 FHUJWWNZPVLGKR-VIFPVBQESA-N 0.000 description 1
- DSJKWQCDVHUQLY-QMMMGPOBSA-N (2s)-1-(3-chloro-4-fluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(F)C(Cl)=C1 DSJKWQCDVHUQLY-QMMMGPOBSA-N 0.000 description 1
- OTCDXKODTDLOAP-QRPNPIFTSA-N (2s)-1-(3-chloro-4-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(F)C(Cl)=C1 OTCDXKODTDLOAP-QRPNPIFTSA-N 0.000 description 1
- ZXBWCAVSVDIMSH-QMMMGPOBSA-N (2s)-1-(3-chloro-5-fluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(F)=CC(Cl)=C1 ZXBWCAVSVDIMSH-QMMMGPOBSA-N 0.000 description 1
- NOBBTCFLCFDHMF-QRPNPIFTSA-N (2s)-1-(3-chloro-5-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC(F)=CC(Cl)=C1 NOBBTCFLCFDHMF-QRPNPIFTSA-N 0.000 description 1
- IWAPFFWHYZQQNO-NSHDSACASA-N (2s)-1-(3-chlorophenyl)-2-ethenylpiperazine Chemical compound ClC1=CC=CC(N2[C@H](CNCC2)C=C)=C1 IWAPFFWHYZQQNO-NSHDSACASA-N 0.000 description 1
- CIVITEGEGCFPHG-NSHDSACASA-N (2s)-1-(3-chlorophenyl)-2-ethylpiperazine Chemical compound CC[C@H]1CNCCN1C1=CC=CC(Cl)=C1 CIVITEGEGCFPHG-NSHDSACASA-N 0.000 description 1
- BOMBMAWLTMFIQD-FVGYRXGTSA-N (2s)-1-(3-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=CC(F)=C1 BOMBMAWLTMFIQD-FVGYRXGTSA-N 0.000 description 1
- VFONQSOGOVFAMO-QRPNPIFTSA-N (2s)-1-(4-chloro-2-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(Cl)C=C1F VFONQSOGOVFAMO-QRPNPIFTSA-N 0.000 description 1
- VNFJVUAMNMWJRT-QMMMGPOBSA-N (2s)-1-(4-chloro-3-fluorophenyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(Cl)C(F)=C1 VNFJVUAMNMWJRT-QMMMGPOBSA-N 0.000 description 1
- KLERMMYBVDMDQN-QRPNPIFTSA-N (2s)-1-(4-chloro-3-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(Cl)C(F)=C1 KLERMMYBVDMDQN-QRPNPIFTSA-N 0.000 description 1
- DJIPSTPEURXLJE-NSHDSACASA-N (2s)-1-(4-chlorophenyl)-2-ethenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1[C@@H](C=C)CNCC1 DJIPSTPEURXLJE-NSHDSACASA-N 0.000 description 1
- FYMXUKMXSGCIIF-NSHDSACASA-N (2s)-1-(4-chlorophenyl)-2-ethylpiperazine Chemical compound CC[C@H]1CNCCN1C1=CC=C(Cl)C=C1 FYMXUKMXSGCIIF-NSHDSACASA-N 0.000 description 1
- FVAIAHKDGNTVEO-FVGYRXGTSA-N (2s)-1-(4-chlorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(Cl)C=C1 FVAIAHKDGNTVEO-FVGYRXGTSA-N 0.000 description 1
- JRCUKWHNBJPBTJ-MERQFXBCSA-N (2s)-1-(4-fluoro-2-methylphenyl)-2,4-dimethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H]1CN(C)CCN1C1=CC=C(F)C=C1C JRCUKWHNBJPBTJ-MERQFXBCSA-N 0.000 description 1
- ZWKYZCYABZNHGL-PPHPATTJSA-N (2s)-1-(4-fluoro-2-methylphenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(F)C=C1C ZWKYZCYABZNHGL-PPHPATTJSA-N 0.000 description 1
- HPRDTDBBKORMMA-FVGYRXGTSA-N (2s)-1-(4-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(F)C=C1 HPRDTDBBKORMMA-FVGYRXGTSA-N 0.000 description 1
- GBLIKOKLIKOWFQ-QRPNPIFTSA-N (2s)-1-(5-chloro-2-fluorophenyl)-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC(Cl)=CC=C1F GBLIKOKLIKOWFQ-QRPNPIFTSA-N 0.000 description 1
- OAYSRGYBHLZBFV-PPHPATTJSA-N (2s)-1-(5-chloro-2-methylphenyl)-2-methylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H]1CNCCN1C1=CC(Cl)=CC=C1C OAYSRGYBHLZBFV-PPHPATTJSA-N 0.000 description 1
- HCDHRWANLGCEPT-FVGYRXGTSA-N (2s)-1-[2-chloro-5-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H]1CN(C)CCN1C1=CC(C(F)(F)F)=CC=C1Cl HCDHRWANLGCEPT-FVGYRXGTSA-N 0.000 description 1
- JFWWIWQETXDOHR-QMMMGPOBSA-N (2s)-1-[2-chloro-5-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC(C(F)(F)F)=CC=C1Cl JFWWIWQETXDOHR-QMMMGPOBSA-N 0.000 description 1
- FASFHBDEESFVEB-QRPNPIFTSA-N (2s)-1-[2-fluoro-3-(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=CC(C(F)(F)F)=C1F FASFHBDEESFVEB-QRPNPIFTSA-N 0.000 description 1
- FLUNPLKTJVUOCZ-FVGYRXGTSA-N (2s)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H]1CN(C)CCN1C1=CC=C(C(F)(F)F)C=C1F FLUNPLKTJVUOCZ-FVGYRXGTSA-N 0.000 description 1
- HHGJORZVLBWSBD-QRPNPIFTSA-N (2s)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(C(F)(F)F)C=C1F HHGJORZVLBWSBD-QRPNPIFTSA-N 0.000 description 1
- KVTDCCWEHFEMBI-VIFPVBQESA-N (2s)-1-[2-fluoro-5-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound C[C@H]1CN(C)CCN1C1=CC(C(F)(F)F)=CC=C1F KVTDCCWEHFEMBI-VIFPVBQESA-N 0.000 description 1
- WHTSMYGJJMMKBA-VIFPVBQESA-N (2s)-1-[3,5-bis(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound C[C@H]1CN(C)CCN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WHTSMYGJJMMKBA-VIFPVBQESA-N 0.000 description 1
- AGJSZFZLRWPVLT-FVGYRXGTSA-N (2s)-1-[3,5-bis(trifluoromethyl)phenyl]-2,4-dimethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H]1CN(C)CCN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AGJSZFZLRWPVLT-FVGYRXGTSA-N 0.000 description 1
- VTLAOTMNWKZTPV-QRPNPIFTSA-N (2s)-1-[3,5-bis(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VTLAOTMNWKZTPV-QRPNPIFTSA-N 0.000 description 1
- BWCOZNJHAUBKKF-QRPNPIFTSA-N (2s)-1-[3-fluoro-5-(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC(F)=CC(C(F)(F)F)=C1 BWCOZNJHAUBKKF-QRPNPIFTSA-N 0.000 description 1
- LOOZOOYWWZXXCP-VIFPVBQESA-N (2s)-1-[4-chloro-3-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound C[C@H]1CN(C)CCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 LOOZOOYWWZXXCP-VIFPVBQESA-N 0.000 description 1
- UMPVEZIMGWSIBK-QMMMGPOBSA-N (2s)-1-[4-chloro-3-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound C[C@H]1CNCCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 UMPVEZIMGWSIBK-QMMMGPOBSA-N 0.000 description 1
- RPQORAHULCDLHN-QRPNPIFTSA-N (2s)-1-[4-chloro-3-(trifluoromethyl)phenyl]-2-methylpiperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 RPQORAHULCDLHN-QRPNPIFTSA-N 0.000 description 1
- KREFAXGNEQIBSV-PPHPATTJSA-N (2s)-2,4-dimethyl-1-[4-(trifluoromethyl)phenyl]piperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H]1CN(C)CCN1C1=CC=C(C(F)(F)F)C=C1 KREFAXGNEQIBSV-PPHPATTJSA-N 0.000 description 1
- AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 description 1
- ZXEIEKDGPVTZLD-NDEPHWFRSA-N (2s)-2-dodecylsulfanyl-n-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide Chemical compound O=C([C@@H](SCCCCCCCCCCCC)C=1C=CC=CC=1)NC1=CC(C)=C(O)C(C)=C1C ZXEIEKDGPVTZLD-NDEPHWFRSA-N 0.000 description 1
- DPIBPWQOZUJLSG-NSHDSACASA-N (2s)-2-ethenyl-1-(3-fluorophenyl)piperazine Chemical compound FC1=CC=CC(N2[C@H](CNCC2)C=C)=C1 DPIBPWQOZUJLSG-NSHDSACASA-N 0.000 description 1
- RUNNQIDZZNXQJI-NSHDSACASA-N (2s)-2-ethyl-1-(3-fluorophenyl)piperazine Chemical compound CC[C@H]1CNCCN1C1=CC=CC(F)=C1 RUNNQIDZZNXQJI-NSHDSACASA-N 0.000 description 1
- ZZGOWKABZUWVJG-NSHDSACASA-N (2s)-2-ethyl-1-(4-fluorophenyl)piperazine Chemical compound CC[C@H]1CNCCN1C1=CC=C(F)C=C1 ZZGOWKABZUWVJG-NSHDSACASA-N 0.000 description 1
- MKOVSSQUDMAZFE-FVGYRXGTSA-N (2s)-2-methyl-1-[4-(trifluoromethyl)phenyl]piperazine;hydrochloride Chemical compound Cl.C[C@H]1CNCCN1C1=CC=C(C(F)(F)F)C=C1 MKOVSSQUDMAZFE-FVGYRXGTSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- FMMUNDXXVADKHS-UHFFFAOYSA-N 1,3-dimethylpiperazine Chemical compound CC1CN(C)CCN1 FMMUNDXXVADKHS-UHFFFAOYSA-N 0.000 description 1
- CDWUIMQWIVPYDR-UHFFFAOYSA-N 1-(2,3-dichlorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=CC(Cl)=C1Cl CDWUIMQWIVPYDR-UHFFFAOYSA-N 0.000 description 1
- HSZORRLOKNAJRD-UHFFFAOYSA-N 1-(2,3-difluorophenyl)-2-ethenylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.FC1=CC=CC(N2C(CNCC2)C=C)=C1F HSZORRLOKNAJRD-UHFFFAOYSA-N 0.000 description 1
- JGISAFRIIXUSKM-UHFFFAOYSA-N 1-(2,3-difluorophenyl)-2-ethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCC1CNCCN1C1=CC=CC(F)=C1F JGISAFRIIXUSKM-UHFFFAOYSA-N 0.000 description 1
- NXZWNQGGMQTIGU-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(Cl)C=C1Cl NXZWNQGGMQTIGU-UHFFFAOYSA-N 0.000 description 1
- SCEDANZPTHLNNQ-UHFFFAOYSA-N 1-(2,5-dichlorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(Cl)=CC=C1Cl SCEDANZPTHLNNQ-UHFFFAOYSA-N 0.000 description 1
- WVBDALRAACLXHH-UHFFFAOYSA-N 1-(2,5-difluoro-4-methoxyphenyl)-2-methylpiperazine Chemical compound C1=C(F)C(OC)=CC(F)=C1N1C(C)CNCC1 WVBDALRAACLXHH-UHFFFAOYSA-N 0.000 description 1
- YRIYHVHGFCRQOS-UHFFFAOYSA-N 1-(2,5-difluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC=C1F YRIYHVHGFCRQOS-UHFFFAOYSA-N 0.000 description 1
- YPNORXBKTKHXMP-UHFFFAOYSA-N 1-(2-bromophenyl)-2-ethenyl-4-(2-nitrophenyl)sulfonylpiperazine Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)N1CC(C=C)N(C=2C(=CC=CC=2)Br)CC1 YPNORXBKTKHXMP-UHFFFAOYSA-N 0.000 description 1
- FGUAGRZQPPGGPW-UHFFFAOYSA-N 1-(2-bromophenyl)-2-ethenylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.BrC1=CC=CC=C1N1C(C=C)CNCC1 FGUAGRZQPPGGPW-UHFFFAOYSA-N 0.000 description 1
- YXSBPRDHVUGCQV-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(F)C=C1Cl YXSBPRDHVUGCQV-UHFFFAOYSA-N 0.000 description 1
- NGJOHYUVUCMCBI-UHFFFAOYSA-N 1-(2-chloro-5-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC=C1Cl NGJOHYUVUCMCBI-UHFFFAOYSA-N 0.000 description 1
- FWVMIKAOFFJLOT-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=CC=C1Cl FWVMIKAOFFJLOT-UHFFFAOYSA-N 0.000 description 1
- SHPCZWDRZCWRGW-UHFFFAOYSA-N 1-(2-fluoro-4-methylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(C)C=C1F SHPCZWDRZCWRGW-UHFFFAOYSA-N 0.000 description 1
- MBYDXRIFXQANNA-UHFFFAOYSA-N 1-(2-fluoro-5-methylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(C)=CC=C1F MBYDXRIFXQANNA-UHFFFAOYSA-N 0.000 description 1
- GTTUADBPLOFPLL-UHFFFAOYSA-N 1-(2-fluoro-5-phenylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(C=2C=CC=CC=2)=CC=C1F GTTUADBPLOFPLL-UHFFFAOYSA-N 0.000 description 1
- ZICABQASCKEIKA-UHFFFAOYSA-N 1-(2-fluorophenyl)-2,4-dimethylpiperazine Chemical compound CC1CN(C)CCN1C1=CC=CC=C1F ZICABQASCKEIKA-UHFFFAOYSA-N 0.000 description 1
- MEPTXPNOKRGNND-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-2-ethylpiperazine;hydrochloride Chemical compound Cl.CCC1CNCCN1C1=CC=C(F)C(F)=C1 MEPTXPNOKRGNND-UHFFFAOYSA-N 0.000 description 1
- QJFFHGINEPHZKD-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(F)C(F)=C1 QJFFHGINEPHZKD-UHFFFAOYSA-N 0.000 description 1
- UOBADTKEGQZGHX-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-2,4-dimethylpiperazine Chemical compound CC1CN(C)CCN1C1=CC(Cl)=CC(Cl)=C1 UOBADTKEGQZGHX-UHFFFAOYSA-N 0.000 description 1
- KWYKEQFSIKSAKJ-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(Cl)=CC(Cl)=C1 KWYKEQFSIKSAKJ-UHFFFAOYSA-N 0.000 description 1
- KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
- WLPZCIXSNMMHHX-UHFFFAOYSA-N 1-(3-bromophenyl)-2-ethenylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.BrC1=CC=CC(N2C(CNCC2)C=C)=C1 WLPZCIXSNMMHHX-UHFFFAOYSA-N 0.000 description 1
- JCFNGCGLBWBQHZ-UHFFFAOYSA-N 1-(3-chloro-2-methylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=CC(Cl)=C1C JCFNGCGLBWBQHZ-UHFFFAOYSA-N 0.000 description 1
- FHUJWWNZPVLGKR-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-2-ethylpiperazine Chemical compound CCC1CNCCN1C1=CC=C(F)C(Cl)=C1 FHUJWWNZPVLGKR-UHFFFAOYSA-N 0.000 description 1
- YIYVNVZSPMVVHO-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-2-ethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCC1CNCCN1C1=CC=C(F)C(Cl)=C1 YIYVNVZSPMVVHO-UHFFFAOYSA-N 0.000 description 1
- NMAJBBPAZUZNGD-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(C)C(Cl)=C1 NMAJBBPAZUZNGD-UHFFFAOYSA-N 0.000 description 1
- ZXBWCAVSVDIMSH-UHFFFAOYSA-N 1-(3-chloro-5-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(Cl)=C1 ZXBWCAVSVDIMSH-UHFFFAOYSA-N 0.000 description 1
- NIRLHBXSHQRSAJ-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-ethylpiperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCC1CNCCN1C1=CC=CC(Cl)=C1 NIRLHBXSHQRSAJ-UHFFFAOYSA-N 0.000 description 1
- QSMGVHJDVRQRLZ-UHFFFAOYSA-N 1-(3-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=CC(F)=C1 QSMGVHJDVRQRLZ-UHFFFAOYSA-N 0.000 description 1
- VNFJVUAMNMWJRT-UHFFFAOYSA-N 1-(4-chloro-3-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(Cl)C(F)=C1 VNFJVUAMNMWJRT-UHFFFAOYSA-N 0.000 description 1
- YNQMSOIMLFQDJT-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-ethylpiperazine;hydrochloride Chemical compound Cl.CCC1CNCCN1C1=CC=C(Cl)C=C1 YNQMSOIMLFQDJT-UHFFFAOYSA-N 0.000 description 1
- RGWQRXKXSCWRNK-UHFFFAOYSA-N 1-(4-fluoro-2-methylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(F)C=C1C RGWQRXKXSCWRNK-UHFFFAOYSA-N 0.000 description 1
- LYNYLGWKAUHVMD-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(F)C=C1 LYNYLGWKAUHVMD-UHFFFAOYSA-N 0.000 description 1
- ONXUKTSFWJTCDE-UHFFFAOYSA-N 1-(5-chloro-2-fluorophenyl)-2,4-dimethylpiperazine Chemical compound CC1CN(C)CCN1C1=CC(Cl)=CC=C1F ONXUKTSFWJTCDE-UHFFFAOYSA-N 0.000 description 1
- GQXWSTBYCKHIDY-UHFFFAOYSA-N 1-(5-chloro-2-fluorophenyl)-2-ethylpiperazine Chemical compound CCC1CNCCN1C1=CC(Cl)=CC=C1F GQXWSTBYCKHIDY-UHFFFAOYSA-N 0.000 description 1
- DHQGBGMOFXIOBH-UHFFFAOYSA-N 1-(5-chloro-2-fluorophenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(Cl)=CC=C1F DHQGBGMOFXIOBH-UHFFFAOYSA-N 0.000 description 1
- UVYOUTBBJYMAPE-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(Cl)=CC=C1C UVYOUTBBJYMAPE-UHFFFAOYSA-N 0.000 description 1
- RKYHQJZSSCACPV-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound CC1CN(C)CCN1C1=CC(C(F)(F)F)=CC=C1Cl RKYHQJZSSCACPV-UHFFFAOYSA-N 0.000 description 1
- JFWWIWQETXDOHR-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(C(F)(F)F)=CC=C1Cl JFWWIWQETXDOHR-UHFFFAOYSA-N 0.000 description 1
- MJMHHRBTVWCAJI-UHFFFAOYSA-N 1-[2-fluoro-3-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=CC(C(F)(F)F)=C1F MJMHHRBTVWCAJI-UHFFFAOYSA-N 0.000 description 1
- XDHGGKCNAPCJMP-UHFFFAOYSA-N 1-[2-fluoro-5-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(C(F)(F)F)=CC=C1F XDHGGKCNAPCJMP-UHFFFAOYSA-N 0.000 description 1
- WHTSMYGJJMMKBA-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound CC1CN(C)CCN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WHTSMYGJJMMKBA-UHFFFAOYSA-N 0.000 description 1
- ZZVDZGWABXAWMX-UHFFFAOYSA-N 1-[3-fluoro-5-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC(F)=CC(C(F)(F)F)=C1 ZZVDZGWABXAWMX-UHFFFAOYSA-N 0.000 description 1
- LOOZOOYWWZXXCP-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]-2,4-dimethylpiperazine Chemical compound CC1CN(C)CCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 LOOZOOYWWZXXCP-UHFFFAOYSA-N 0.000 description 1
- UMPVEZIMGWSIBK-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]-2-methylpiperazine Chemical compound CC1CNCCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 UMPVEZIMGWSIBK-UHFFFAOYSA-N 0.000 description 1
- PMGZJNCIQHGNLT-UHFFFAOYSA-N 1-[bis(2,2-dimethylpropanoyloxymethoxy)phosphoryl]-4-(3-phenoxyphenyl)butane-1-sulfonic acid Chemical compound CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)C(S(O)(=O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 PMGZJNCIQHGNLT-UHFFFAOYSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- RKWWASUTWAFKHA-UHFFFAOYSA-N 1-bromo-2,3-difluorobenzene Chemical compound FC1=CC=CC(Br)=C1F RKWWASUTWAFKHA-UHFFFAOYSA-N 0.000 description 1
- MGHBDQZXPCTTIH-UHFFFAOYSA-N 1-bromo-2,4-difluorobenzene Chemical compound FC1=CC=C(Br)C(F)=C1 MGHBDQZXPCTTIH-UHFFFAOYSA-N 0.000 description 1
- JRGGUPZKKTVKOV-UHFFFAOYSA-N 1-bromo-3-chlorobenzene Chemical compound ClC1=CC=CC(Br)=C1 JRGGUPZKKTVKOV-UHFFFAOYSA-N 0.000 description 1
- MHRRZKUNYYQXTA-UHFFFAOYSA-N 1-chloro-2-fluoro-3-iodobenzene Chemical compound FC1=C(Cl)C=CC=C1I MHRRZKUNYYQXTA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- YCCQGFYAVUTQFK-UHFFFAOYSA-N 2,3-difluoroaniline Chemical compound NC1=CC=CC(F)=C1F YCCQGFYAVUTQFK-UHFFFAOYSA-N 0.000 description 1
- ZKFMOOPNQZESSI-UHFFFAOYSA-N 2,4-dimethyl-1-[3-(trifluoromethyl)phenyl]piperazine Chemical compound CC1CN(C)CCN1C1=CC=CC(C(F)(F)F)=C1 ZKFMOOPNQZESSI-UHFFFAOYSA-N 0.000 description 1
- VRTRBJXZWCDLSX-UHFFFAOYSA-N 2,4-dimethyl-1-[4-(trifluoromethyl)phenyl]piperazine Chemical compound CC1CN(C)CCN1C1=CC=C(C(F)(F)F)C=C1 VRTRBJXZWCDLSX-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- PHLPNEHPCYZBNZ-UHFFFAOYSA-N 2-(2-ditert-butylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C PHLPNEHPCYZBNZ-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- QKRJIXSZTKOFTD-UHFFFAOYSA-N 2-bromo-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1Br QKRJIXSZTKOFTD-UHFFFAOYSA-N 0.000 description 1
- WEMDUNBELVTSRP-UHFFFAOYSA-N 2-bromo-4-propan-2-ylaniline Chemical compound CC(C)C1=CC=C(N)C(Br)=C1 WEMDUNBELVTSRP-UHFFFAOYSA-N 0.000 description 1
- AOPBDRUWRLBSDB-UHFFFAOYSA-N 2-bromoaniline Chemical compound NC1=CC=CC=C1Br AOPBDRUWRLBSDB-UHFFFAOYSA-N 0.000 description 1
- WJAXXWSZNSFVNG-UHFFFAOYSA-N 2-bromoethanamine;hydron;bromide Chemical compound [Br-].[NH3+]CCBr WJAXXWSZNSFVNG-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- DLAJDDIJFVIGQN-UHFFFAOYSA-N 2-ethenyl-1-(3-fluorophenyl)piperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.FC1=CC=CC(N2C(CNCC2)C=C)=C1 DLAJDDIJFVIGQN-UHFFFAOYSA-N 0.000 description 1
- BEASRCYADRLPOC-UHFFFAOYSA-N 2-ethenyl-1-(4-fluorophenyl)piperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(F)=CC=C1N1C(C=C)CNCC1 BEASRCYADRLPOC-UHFFFAOYSA-N 0.000 description 1
- RUNNQIDZZNXQJI-UHFFFAOYSA-N 2-ethyl-1-(3-fluorophenyl)piperazine Chemical compound CCC1CNCCN1C1=CC=CC(F)=C1 RUNNQIDZZNXQJI-UHFFFAOYSA-N 0.000 description 1
- PIFKCORDZRLICP-UHFFFAOYSA-N 2-ethyl-1-(3-fluorophenyl)piperazine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCC1CNCCN1C1=CC=CC(F)=C1 PIFKCORDZRLICP-UHFFFAOYSA-N 0.000 description 1
- DXOHZOPKNFZZAD-UHFFFAOYSA-N 2-ethylpiperazine Chemical compound CCC1CNCCN1 DXOHZOPKNFZZAD-UHFFFAOYSA-N 0.000 description 1
- GDUWSJMPXLBYPG-UHFFFAOYSA-N 2-methyl-1-[4-(trifluoromethyl)phenyl]piperazine Chemical compound CC1CNCCN1C1=CC=C(C(F)(F)F)C=C1 GDUWSJMPXLBYPG-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- SWBDKCMOLSUXRH-UHFFFAOYSA-N 2-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=CC=C1C#N SWBDKCMOLSUXRH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UQRLKWGPEVNVHT-UHFFFAOYSA-N 3,5-dichloroaniline Chemical compound NC1=CC(Cl)=CC(Cl)=C1 UQRLKWGPEVNVHT-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- NXHKKQGYYRVCIL-GFCCVEGCSA-N 3-[(2r)-2-ethenylpiperazin-1-yl]benzonitrile Chemical compound C=C[C@@H]1CNCCN1C1=CC=CC(C#N)=C1 NXHKKQGYYRVCIL-GFCCVEGCSA-N 0.000 description 1
- NXHKKQGYYRVCIL-LBPRGKRZSA-N 3-[(2s)-2-ethenylpiperazin-1-yl]benzonitrile Chemical compound C=C[C@H]1CNCCN1C1=CC=CC(C#N)=C1 NXHKKQGYYRVCIL-LBPRGKRZSA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- YMQPKONILWWJQG-UHFFFAOYSA-N 4-bromo-1,2-difluorobenzene Chemical compound FC1=CC=C(Br)C=C1F YMQPKONILWWJQG-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- VFFZWMWTUSXDCB-ZDUSSCGKSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VFFZWMWTUSXDCB-ZDUSSCGKSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000054930 Agouti-Related Human genes 0.000 description 1
- 101710127426 Agouti-related protein Proteins 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 229940127438 Amylin Agonists Drugs 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- GGUVRMBIEPYOKL-WMVCGJOFSA-N GW 409544 Chemical compound C([C@H](NC(/C)=C\C(=O)C=1C=CC=CC=1)C(O)=O)C(C=C1)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 GGUVRMBIEPYOKL-WMVCGJOFSA-N 0.000 description 1
- YDBLKRPLXZNVNB-UHFFFAOYSA-N GW 501516 Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1CSC1=CC=C(OCC(O)=O)C(C)=C1 YDBLKRPLXZNVNB-UHFFFAOYSA-N 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010016122 Ghrelin Receptors Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 1
- 101000928179 Homo sapiens Agouti-related protein Proteins 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 108010000410 MSH receptor Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 229940127308 Microsomal Triglyceride Transfer Protein Inhibitors Drugs 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102000030937 Neuromedin U receptor Human genes 0.000 description 1
- 108010002741 Neuromedin U receptor Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 208000007301 Night Eating Syndrome Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 1
- 208000034992 Orthorexia Nervosa Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 241001482237 Pica Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000011390 Rumination Syndrome Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 108091064432 SbRNA Proteins 0.000 description 1
- 206010039917 Selective mutism Diseases 0.000 description 1
- 208000022890 Sleep-related eating disease Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001125929 Trisopterus luscus Species 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- 102000005630 Urocortins Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- YWCXEJRLXUMTBK-HYXAFXHYSA-N [(z)-4-methoxycarbonyloxybut-1-enyl] methyl carbonate Chemical compound COC(=O)OCC\C=C/OC(=O)OC YWCXEJRLXUMTBK-HYXAFXHYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000005937 allylation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002426 anti-panic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 1
- 208000022266 body dysmorphic disease Diseases 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001723 carbon free-radicals Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 229950005749 ceronapril Drugs 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 206010062937 cyclic vomiting syndrome Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- SVABQOITNJTVNJ-UHFFFAOYSA-N diphenyl-2-pyridylphosphine Chemical compound C1=CC=CC=C1P(C=1N=CC=CC=1)C1=CC=CC=C1 SVABQOITNJTVNJ-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000035548 disruptive behavior disease Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229950005925 eflucimibe Drugs 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 102000055839 human AGRP Human genes 0.000 description 1
- 102000046783 human APP Human genes 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 229950005809 implitapide Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 229950001628 netoglitazone Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000009907 neuroendocrine response Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical group [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 230000020964 regulation of blood coagulation Effects 0.000 description 1
- 230000013333 regulation of fatty acid metabolic process Effects 0.000 description 1
- 230000029556 regulation of feeding behavior Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 235000019553 satiation Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 229960002909 spirapril Drugs 0.000 description 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
- 108700035424 spirapril Proteins 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- FMLPQHJYUZTHQS-MRVPVSSYSA-N tert-butyl (3r)-3-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-MRVPVSSYSA-N 0.000 description 1
- GOQUHQPTIASZMI-IVAFLUGOSA-N tert-butyl 4-[(1r)-1-(4-chlorophenyl)-6-methylcyclohexa-2,4-dien-1-yl]piperazine-1-carboxylate Chemical compound CC1C=CC=C[C@@]1(C=1C=CC(Cl)=CC=1)N1CCN(C(=O)OC(C)(C)C)CC1 GOQUHQPTIASZMI-IVAFLUGOSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 239000003749 thyromimetic agent Substances 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48004503P | 2003-06-20 | 2003-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200510256B true ZA200510256B (en) | 2006-12-27 |
Family
ID=34193031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200510256A ZA200510256B (en) | 2003-06-20 | 2005-12-15 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases |
Country Status (13)
Country | Link |
---|---|
US (1) | US20070179155A1 (fr) |
EP (1) | EP1644347A1 (fr) |
JP (1) | JP2007523861A (fr) |
KR (1) | KR20060065584A (fr) |
CN (1) | CN1809545A (fr) |
AU (1) | AU2004265243A1 (fr) |
BR (1) | BRPI0411661A (fr) |
CA (1) | CA2529750A1 (fr) |
EA (1) | EA200600071A1 (fr) |
IL (1) | IL172564A0 (fr) |
MX (1) | MXPA05013365A (fr) |
WO (1) | WO2005016902A1 (fr) |
ZA (1) | ZA200510256B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2006140687A (ru) * | 2004-06-18 | 2008-07-27 | Ньюросерч А/С (DK) | Новые алкил-замещенные производные пиперазина и их применение в качестве ингибиторов обратного захвата моноаминовых нейротрансмиттеров |
EP2248524A3 (fr) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Agents preventifs/remedes pour l'incontinence de stress et procede de selecetion de ceux-ci |
CN101084206A (zh) * | 2004-12-13 | 2007-12-05 | 艾尼纳制药公司 | 作为5ht2c受体调节剂以治疗与其相关病症的n-联芳基和n-芳基杂芳基2-经取代哌嗪衍生物 |
EP1844792A4 (fr) * | 2004-12-14 | 2008-05-21 | Shionogi & Co | Agent therapeutique pour la constipation |
SI1833473T1 (sl) | 2004-12-23 | 2010-01-29 | Arena Pharm Inc | Sestavki modulatorjev 5HT2C receptorjev in postopki uporabe |
ITMI20051193A1 (it) * | 2005-06-24 | 2006-12-25 | Acraf | Uso farmaceutico di una 1-3-clorofenil-3-alchilpiperazina |
EP2742936A1 (fr) | 2006-05-16 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique condensé et son utilisation |
EP2789338A3 (fr) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Dérivé de pyridine condensé et son utilisation |
CN102015668A (zh) | 2007-12-05 | 2011-04-13 | 阿斯利康(瑞典)有限公司 | 用作瘦蛋白受体调节剂的哌嗪衍生物及其用途 |
EP2229362A1 (fr) | 2007-12-05 | 2010-09-22 | AstraZeneca AB | Pipérazines comme agents anti-obésité |
WO2009148891A1 (fr) * | 2008-05-30 | 2009-12-10 | Psychogenics, Inc. | Traitement pour des troubles neurologiques et mentaux |
JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
ES2533990T3 (es) * | 2010-02-24 | 2015-04-16 | Research Triangle Institute | Antagonistas de receptores opioides de arilpiperazina |
CN103189360A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的非吸湿性盐 |
EP3485878A1 (fr) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Formes posologiques à libération modifiée d'agonistes de 5-ht2c utiles pour la gestion du poids |
MX2013002422A (es) | 2010-09-01 | 2013-05-17 | Arena Pharm Inc | Sales de lorcaserina con acidos opticamente activos. |
US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
SG188365A1 (en) | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Administration of lorcaserin to individuals with renal impairment |
AU2012392187B2 (en) | 2012-10-09 | 2018-07-12 | Arena Pharmaceuticals, Inc. | Method of weight management |
GB201309967D0 (en) * | 2013-06-04 | 2013-07-17 | Cambridge Entpr Ltd | Therapeutic combinations |
WO2015066344A1 (fr) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation |
EP3733204A4 (fr) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | Agent thérapeutique pour incontinence urinaire de stress et incontinence fécale |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3247206A (en) * | 1962-10-05 | 1966-04-19 | Ciba Geigy Corp | Diaza-cycloalkane synthesis |
US3253989A (en) * | 1963-02-11 | 1966-05-31 | American Cyanamid Co | Process for producing anorexia |
US3751417A (en) * | 1971-08-12 | 1973-08-07 | American Cyanamid Co | 1-acyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)indolines |
US4082844A (en) * | 1976-02-09 | 1978-04-04 | Merck & Co., Inc. | 6-chloro-2-(1-piperazinyl)pyrazine |
US4210753A (en) * | 1976-03-17 | 1980-07-01 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds |
JPS54130587A (en) * | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
US4426383A (en) * | 1980-09-04 | 1984-01-17 | Eisai Co., Ltd. | Theophylline and theobromine derivatives |
DE3364234D1 (en) * | 1982-03-02 | 1986-07-31 | Eisai Co Ltd | Antiphlogistic/antipyretic/analgesic pharmaceutical compositions containing theophylline derivatives as active ingredient |
US4457931A (en) * | 1982-09-27 | 1984-07-03 | Selvi & C. S.P.A. | Piperazine derivatives with anticholinergic and/or antihistaminic activity |
US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
IN164921B (fr) * | 1986-07-22 | 1989-07-08 | Hoechst India | |
ES2061953T3 (es) * | 1988-11-24 | 1994-12-16 | Akzo Nv | Un procedimiento para preparar una composicion farmaceutica. |
US5912246A (en) * | 1995-02-15 | 1999-06-15 | Pharmacia & Upjohn Company | Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases |
WO1998000400A1 (fr) * | 1996-06-28 | 1998-01-08 | Meiji Seika Kaisha, Ltd. | Composes de tetrahydrobenzindole |
JP2001526643A (ja) * | 1997-04-18 | 2001-12-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環 |
IL123986A (en) * | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
WO1999000366A1 (fr) * | 1997-06-27 | 1999-01-07 | Nippon Kayaku Kabushiki Kaisha | Medicaments pour le traitement/la prevention des mictions frequentes et de l'incontinence urinaire, et derives de tropone |
ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
AR022687A1 (es) * | 1998-12-17 | 2002-09-04 | Wyeth Corp | Derivados de 2,3,4,4a-tetrahidro-1h-pirazino[1,2-a] quinoxalin-5(6h)ona, una composicion farmaceutica y el uso de los mismos para la manufactura de losmedicamentos. |
US6465467B1 (en) * | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
EP1204654B1 (fr) * | 1999-07-29 | 2003-07-23 | Eli Lilly And Company | Benzofurylpiperazines: agonistes du recepteur 5-ht2c de la serotonine |
US20030073701A1 (en) * | 2001-03-31 | 2003-04-17 | Thompson Lorin A. | Succinoylamino heterocycles as inhibitors of a beta protein production |
US6683093B2 (en) * | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
JP4021602B2 (ja) * | 2000-06-16 | 2007-12-12 | 株式会社東芝 | 半導体記憶装置 |
JP4102185B2 (ja) * | 2000-06-30 | 2008-06-18 | グラクソ グループ リミテッド | キナゾリンジトシル酸塩化合物 |
GB0025056D0 (en) * | 2000-10-12 | 2000-11-29 | Smithkline Beecham Spa | Novel compounds |
AU2002224038B2 (en) * | 2000-11-15 | 2006-03-09 | Banyu Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
DE10057751A1 (de) * | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
GB0030710D0 (en) * | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
DE60205727T2 (de) * | 2001-01-23 | 2006-06-29 | Eli Lilly And Co., Indianapolis | Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors |
CA2443724C (fr) * | 2001-05-11 | 2009-11-03 | Patrizia Caldirola | Composes arylsulfonamide pour le traitement de l'obesite, de diabetes de type ii et de troubles du systeme nerveux central |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
DE10134721A1 (de) * | 2001-07-17 | 2003-02-06 | Bayer Ag | Tetrahydrochinoxaline |
US20030073781A1 (en) * | 2001-08-14 | 2003-04-17 | Chang Chun Plastics Co., Ltd. | Phosphorus-containing resin and flame retardant resin composition containing the same |
CA2430328A1 (fr) * | 2001-09-28 | 2003-04-10 | Kyowa Hakko Kogyo Co., Ltd. | Antagoniste de recepteur |
DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
DE10261131A1 (de) * | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
CN100335462C (zh) * | 2003-09-05 | 2007-09-05 | 清华大学 | 咔唑衍生物及其在电致发光器件中的应用 |
US7230002B2 (en) * | 2004-02-03 | 2007-06-12 | Glenmark Pharmaceuticals Ltd. | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof |
-
2004
- 2004-06-17 CN CNA2004800170011A patent/CN1809545A/zh active Pending
- 2004-06-17 AU AU2004265243A patent/AU2004265243A1/en not_active Abandoned
- 2004-06-17 WO PCT/US2004/019540 patent/WO2005016902A1/fr active Application Filing
- 2004-06-17 EA EA200600071A patent/EA200600071A1/ru unknown
- 2004-06-17 EP EP04776755A patent/EP1644347A1/fr not_active Withdrawn
- 2004-06-17 MX MXPA05013365A patent/MXPA05013365A/es not_active Application Discontinuation
- 2004-06-17 CA CA002529750A patent/CA2529750A1/fr not_active Abandoned
- 2004-06-17 US US10/561,101 patent/US20070179155A1/en not_active Abandoned
- 2004-06-17 BR BRPI0411661-5A patent/BRPI0411661A/pt not_active IP Right Cessation
- 2004-06-17 KR KR1020057024354A patent/KR20060065584A/ko not_active Application Discontinuation
- 2004-06-17 JP JP2006517403A patent/JP2007523861A/ja not_active Withdrawn
-
2005
- 2005-12-13 IL IL172564A patent/IL172564A0/en unknown
- 2005-12-15 ZA ZA200510256A patent/ZA200510256B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20070179155A1 (en) | 2007-08-02 |
CN1809545A (zh) | 2006-07-26 |
JP2007523861A (ja) | 2007-08-23 |
EA200600071A1 (ru) | 2006-08-25 |
MXPA05013365A (es) | 2006-04-05 |
WO2005016902A1 (fr) | 2005-02-24 |
EP1644347A1 (fr) | 2006-04-12 |
AU2004265243A1 (en) | 2005-02-24 |
IL172564A0 (en) | 2006-04-10 |
KR20060065584A (ko) | 2006-06-14 |
BRPI0411661A (pt) | 2006-08-29 |
CA2529750A1 (fr) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200510256B (en) | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases | |
AU2004253888B2 (en) | Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases | |
AU2005322183B2 (en) | 5HT2C receptor modulator compositions and methods of use | |
US20080009478A1 (en) | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | |
US20070275949A1 (en) | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | |
US20080119477A1 (en) | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | |
US20080255137A1 (en) | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | |
AU2012201515B2 (en) | 5HT2C receptor modulator compositions and methods of use |